Media coverage about Shire (NASDAQ:SHPG) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Shire earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.923087278091 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s rankings:
- What Analysts Say? Shire plc (SHPG) stock closes Yesterday with -0.35% – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Shire plc : Elections for the interim dividend in respect of the six months to December 31, 2017 – GlobeNewswire (press release) (globenewswire.com)
- Is the Stock Safe to Invest? – Shire plc (NASDAQ: SHPG) – Alpha Beta Stock (alphabetastock.com)
- Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society’s 2018 Annual … – GlobeNewswire (press release) (globenewswire.com)
- Shire To Present Advancements In Chronic Hypoparathyroidism Research – Nasdaq (nasdaq.com)
Shares of Shire (NASDAQ:SHPG) traded up $1.34 during trading hours on Wednesday, hitting $132.56. The stock had a trading volume of 524,401 shares, compared to its average volume of 1,270,000. The firm has a market cap of $40,130.00, a P/E ratio of 21.84, a price-to-earnings-growth ratio of 0.77 and a beta of 1.43. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.97 and a quick ratio of 0.55. Shire has a 12 month low of $123.73 and a 12 month high of $192.15.
The firm also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Friday, March 9th will be paid a $0.8937 dividend. This represents a dividend yield of 1.33%. This is an increase from Shire’s previous semiannual dividend of $0.15. The ex-dividend date of this dividend is Thursday, March 8th. Shire’s payout ratio is currently 17.30%.
Several research analysts have commented on the company. Cantor Fitzgerald set a $222.00 target price on Shire and gave the stock a “buy” rating in a report on Wednesday, March 7th. BidaskClub raised Shire from a “strong sell” rating to a “sell” rating in a report on Friday, March 2nd. SunTrust Banks cut their target price on Shire to $190.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Shire in a report on Tuesday, February 20th. Finally, Royal Bank of Canada cut their target price on Shire to $181.00 and set an “outperform” rating on the stock in a report on Friday, February 16th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. Shire currently has a consensus rating of “Buy” and an average target price of $204.00.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://baseballnewssource.com/2018/03/14/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-shire-shpg-stock-price/2031025.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.